Down's syndrome (DS) subjects are at high risk of developing Alzheimer's disease (AD). Patients with AD often show altered levels of some immune molecules in their peripheral blood which correlate with cognitive impairment. However, whether the altered peripheral immune phenotype is a late and secondary phenomenon associated with dementia or an early impairment linked to mechanisms controlling neurodegeneration of the central nervous system (CNS) is still an unanswered question. Here we studied immune molecules in the blood of non demented children with DS to investigate whether altered peripheral immune phenotype could be present in these subjects without dementia, many years before the presentation of clinical signs of cognitive deterioration. Plasma levels of interleukin-6 (IL-6) and soluble IL-6 receptor (sIL-6R) were significantly higher in DS than in control children. Plasma levels of soluble intercellular adhesion molecule-3 (sICAM-3), soluble vascular cell adhesion molecule-l (sVCAM-l) and C reactive protein (CRP) were also increased in DS. The increase of IL-6 and CRP from DS children was similar to that found in elderly patients with clinical AD. Peripheral altered immune phenotype in healthy young subjects with DS might be an early sign of CNS alterations leading many years later to cognitive deterioration and dementia.
mRNA of complement components are also over produced in brains from AD patients (14) (15) . It is interesting to note that IL-l and complement components have also been associated with degenerate neurons and beta-amyloid deposition in the brains of DS aged individuals (9, 16) .
The above findings contribute to the hypotheses that cytokines and other molecules with immune regulatory functions play a primary role in inflammatory reactions associated with degenerative alterations in the AD brain (17) (18) , and that altered immune responses, usually called neuroinflammation, are associated with the pathogenesis of the disease (19) . Recent findings regarding the association of gene polymorphism in cytokines and acute phase proteins genes with an increased risk of AD (8, 19) reinforced the notion that impaired immune responses are linked to the pathogenesis of the disease.
Altered immune reactivity is also detectable in the peripheral blood of patients with clinical AD. For instance, elevated levels of IL-l, IL-6 and a-l-antichymotripsin (ACT) have been found in AD (20) (21) (22) (23) (24) and the plasma levels of ACT correlated with the cognitive status in these patients (24) . However, other investigations have not found increased IL-6 (25) (26) or ACT levels (27) (28) (29) in the blood of AD patients. Altered immune response is frequently observed in DS subjects, even at an early age (30) (31) , and has been considered responsible for the high morbidity for infections in the syndrome. Few data regarding blood cytokines and their relations with cognitive decline in DS are on record. A recent investigation has shown that plasma levels of the macrophage inhibiting protein-l (MIP-I) and IL-6 were higher in a small group of adult DS than in non DS mentally retarded controls and levels ofIL-6 correlated with the degree of mental retardation only in DS subjects (32) .
In the present study the relationship between DS, mental impairment, AD and blood levels of cytokines and other immune regulatory molecules was further investigated.
MATERIALS AND METHODS

Subjects
Two groups of children were studied: group I consisted of 20 apparently healthy controls (age 5-10 years); group 2 consisted of 40 children with trisomy 21 (age 5-10 years). Down's syndrome was assessed by clinical examination and karyotype analysis. Both controls and DS were in good health status. All DS children were living at home and attending first degree schools, showed a mild and variable degree of mental retardation and were free of other pathological conditions at the moment of the study. Comprehension ability was assessed for each DS child, as previously described (31) . DS children were participating to a nutritional study and informed consent was obtained from one parent. Informed consent was also obtained from control's parents. The protocol was approved by Ethics Committee of University of Bologna and by Fondazione Antoniana of Bologna.
Patients with clinical AD (n = 100, age = 69 ± 2 years) and non demented elderly (n =128, age =74 ± 2 years) were selected at the Neurology Department of the San Raffaele Hospital and the Geriatric Department, University of Milan, Italy. Clinical diagnosis of AD was performed according the DMS-III-R and NINCDS-ADRDA criteria (33) . Informed consent was obtained from a relative of the AD patient and from elderly controls. Only AD and controls without clinical signs of inflammation, normal body temperature and without concomitant inflammatory disease were admitted to the study. Patients or controls with abnormal sedimentation rate of red blood cells and altered blood albumin and/or transferrin were not included.
Laboratory procedures
Blood samples were colIected from DS subjects, AD patients and controls after an overnight fasting at 8.00 a.m. using EDT A as an anticoagulant. Plasma was obtained by centrifugation (1500 g for 15min), transferred into coded plastic tubes, rapidly frozen and stored at -20°C until analysis.
Interleukin-6 (lL-6) and interleukin-6 soluble receptor (sIL-6R) concentrations were evaluated using a Quantikine Enzyme-Linked ImmunoSorbent Assay (ELISA) kit (R&D Systems, UK), according to the manufacturer's recommendations. The minimum detectable plasma concentration was 0.70 pg/ml for IL-6 and 6.5 pg/ml for sIL-6R.
Plasma C reactive protein (CRP) concentration form DS and control children was evaluated by LANIA (Latex Agglutination Nephelometric Immunoassay) technique (Biolatex, Spain). Samples were diluted 1:36 and results were calculated automatically by IMMAGE system. The minimum detectable concentration was 0.4 mg/dl. Plasma CRP levels from AD and elderly controls were detected by radial immune-diffusion assay (NANORID, The binding Site, UK), as previously described (24) .
Plasma levels of neopterin were measured by commercially available ELISA kits (BRAHMS Elitest, Germany).
Plasma sICAM-I concentration was evaluated in plasmabya BIOSOURCE EASIAkit (BioSource Europe, Belgium). The sensitivity of the assay was 0.3 ng/ml. Plasma sICAM-3 concentration was measured by an ELISA kit (MedSystems Diagnostics GmbH, Austria). The sensitivity of the assay was 0.58 ng/ml. Plasma levels of sVCAM-l were detected by an ELISA kit (MedSystems Diagnostics GmbH, Austria). Plasma samples were diluted I:50 with assay buffer. The sensitivity of the assay was 0.9 ng/rnl,
Statistical analysis
The results are given as mean ± standard deviation (SD).GraphPadInStat3.0 software(GraphPadSoftware, Inc., San Diego, CA, USA) was used to compare data from DS and controls by unpaired t test. A p-value of <0.05 was considered statistically significant. Linear regression analysis between experimental variables was assessed by SPSS statistical software.
RESULTS
As shown in Fig.1 (panel A) , plasma levels of IL-6 were higher in DS than in control children (Controls =0.49 ± 0.1; DS =2.1 ± 1 pg/ ml, p < 0.0001). Levels of soluble IL-6 receptor (sIL-6R) was also significantly increased in DS children (Fig 1, panel B ; Controls =39 ± 13; DS = 108 ± 19 pg/ml, p < 0.0001).
Levels of soluble sICAM-3 were slightly increased in DS, as reported in Figure 2 , panel A (Controls =47 ± 10; DS =63 ±18 ng/ml, p < 0.05).
Plasma levels of soluble sVCAM-1 (sVCAM-1) were also slightly higher in DS than in control children, as shown in Fig. 2, Blood levels of eRP were higher in DS than in controls children, as illustrated in Fig. 3 (Controls 1.3 ± 0.3; DS =5.7 ± 4.6 mg/L, p < 0.01). Plasma levels of neopterin or ICAM-1 between controls and DS were comparable, as reported in Table I .
A comparison between IL-6, CRP and neopterin plasma levels from DS children and elderly patients with AD is shown in Table II . Data were normalized by calculating the ratio between DS data and those from their age matched controls and AD and their age matched controls. Both IL-6 and CRP levels were increased in plasma from DS and AD, whilst levels of neopterin were in the normal range either in DS or AD.
IL-6 levels did not correlated with mental performances, as assessed by comprehension tests. However, plasma IL-6R levels positively correlated with chronological age (r =0.41, P < 0.01) and comprehension age-test (r = 0.48, p < 0.01).
DISCUSSION
IL-6 is a cytokine with pleiotropic immune functions secreted by a number of different cells, including activated macrophages, lymphocytes and endothelial cells and it has been suggested of particular interest for gerontologist (34) . The biological actions induced by IL-6 are initiated by binding to a high affinity receptor complex, i.e. a two membrane glycoprotein receptor (35) . A soluble form of IL-6R (sIL-6R) with a molecular weight of approximately 50 kDa has been also described. sIL-6R apparently arises from the proteolytic cleavage of the membrane bound IL-6R, is able to bind secreted IL-6 and may increase the immune function of this cytokine as a result of DS reacti ve response to brain pathology or also played an active role in the pathogenesis of AD. However, subsequent studies showing an association between gene polymorphism of the promoter region in IL-6 gene and AD risk further reinforced the notion of a primary link between this cytokine and the disease (39) . Middle age DS subjects are at elevated risk of developing AD-like brain alterations and AD-like cognitive deterioration (4) (5) . However, it has been shown that the production of soluble amyloid peptide and amyloid deposition in the DS brain is increased since the early stage of life in these subjects (40) . Therefore, DS may be an interesting model to study the relationship between altered immune responses and mechanisms leading to neurodegeneration associated with AD.
Here we found that young non demented DS children, without clinical signs of inflammation or systemic diseases inducing the activation of immune responses, showed higher levels of IL-6 and sIL-6R than age matched controls. Other molecules, such as sICAM-3 and sVCAM-I, usually released by activated endothelial cells (41) , were also slightly elevated in DS children along with a modest but significant increase of CRP.
Our data parallel those from Carta and coworkers (32) showing that circulating levels of another cytokine, named macrophage inhibiting protein-La (MIP-I<x), and those of IL-6 were elevated in adult with DS.
An increase ofIL-6 and CRP circulating levels similar to that observed in DS was also found in a group of patients with clinical diagnosis of AD. Both IL-6 and CRP are produced by several cell types and tissues including hepatocytes, macrophages, glia and endothelia. To investigate whether these cytokines and acute phase reactants might be released by activated peripheral immune system the neopterin plasma levels were also measured. Neopterin is a stable metabolite derived from guanosine triphosphate, released by the activated monocytes and macrophages (42) . Plasma levels of neopterin in DS children and AD patients was comparable to levels observed in their respective control group.
Increased (43-44) or normal levels (24) of this metabolite have been found in the blood of AD patients. However, increased blood neopterin was likely to be only elevated in patients with the binding of the IL-6/sIL-6R complex to the membrane bound gp 130 protein (36) (37) . It has been also suggested that increased secretion ofIL-6 are associated with elevated production of sIL-6R. Elevated IL-6 circulating levels have been described in ageing and have beeri correlated with the age associated fraility (38) . Increased plasma IL-6 (24, 39) or serum sIL-6R levels have also been reported in patients with AD (26) .
Previous investigations from our group suggested that elevated plasma levels of this cytokine in AD was not likely to be ascribed to the activation of peripheral immune responses, but to immune signals from the brain, possibly derived from activated endothelia surrounding the brain areas with neurodegenerative processes (24) . Nevertheless, it was unclear whether this inappropriate levels of IL-6 was a secondary advanced clinical stage of AD (45).
The findings presented here confirm our previous neopterin data (24) in AD and extend this observation in DS subjects. It is important to note that both AD and DS were negatively selected for the presence of clinical inflammatory states to exclude possible false positive due to other concomitant clinical conditions. Therefore, the normal levels of neopterin in AD and DS did not support the view of a systemic peripheral activation of the immune system in these subjects.
Our data regarding increased sICAM-3 and sYCAM-l in DS plasma is the first study on this topic in DS and also suggest the presence of mild activation and lor moderate dysfunction of endothelial cells in these subjects.
Elevated levels of IL-6 and intercellular adhesion molecules also reflect endothelial dysfunction in different pathological conditions, such as atherosclerosis and its complications (46). However, DS is considered a human condition with low clinical atherosclerosis manifestation and low cardiovascular disease's risk during adulthood and ageing (47-48).
In the absence of peripheral and systemic activation of immune system, increased levels of IL-6, sIL-6R, sICAM-3 and sYCAM-l in DS blood might be ascribed to elevated secretion of these compounds by activated vessels form CNS or directly by the brain, as suggested for IL-6 by other investigations, (49). These findings reinforce the notion that circulating IL-6 and its soluble receptor might be sensitive peripheral markers of pathological processes involving the CNS in DS and AD.
It is of interest that sIL-6R plasma levels from DS positively correlated with chronological age and with the mental performances as assessed by comprehension age capability. Therefore, an impaired regulation of IL-6/sIL-6R metabolism might parallel the abnormal development of central nervous system (CNS) in early stages of DS life and/or the ongoing concomitant degenerative processes eventually leading to AD like pathology and AD like dementia later in the adulthood. In fact, this impaired IL-6/sIL-6R regulation was apparent in young DS with mild mental retardation and without clinical evidence of cognitive impairment. Our findings parallel other data showing that levels of IL-6 and MIP-l a correlated with the degree of mental retardation in adult DS but not in mentally retarded controls (32) . Other investigations also showed that serum IL-61evels correlated with the severity of dementia in both DS and AD (21) . It is of interest to note that elevated plasma IL-6 predicted subsequent decline ofcognitive functions in subjects from the MacArthur Study of Successful Aging (50). On the other hand it has been reported from a large longitudinal study that increased blood CRP was associated with increased risk of developing dementia in men (51). These findings showed that different markers of altered immune activation, usually interpreted as systemic inflammation, were linked to the development of senile cognitive impairment and dementia. IL-6/sIL-6Ra transgenic mouse model exhibited systemic elevation of IL-6 and sIL-6R, massive reactive gliosis without initial neuronal alterations, and no significant leakage of blood brain barrier, suggesting that these cytokines may selectively target astrocytes (52). Impaired secretion of IL-6 and sIL-6R by activated brain endothelia or stressed neuronal cells in DS and pre-clinical AD might induce an abnormal activation ofastroglia cells and contribute to neuronal degeneration leading to clinical dementia. However, Its has also been shown that IL-6 belong to a family of neurotrophic molecules (53-54). Therefore, at the moment we could not exclude the hypothesis that increased IL-6 levels in very young DS subjects might be an emergency response of immune system to an ongoing neurodegeneration.
